Sigmovir Biosystems
Private Company
Total funding raised: $17.5M
Overview
Sigmovir Biosystems is a specialized contract research organization (CRO) and animal model provider focused exclusively on the cotton rat model for infectious diseases. Founded in 2015, the company capitalizes on over 100 years of combined team experience with this model, which is considered superior to standard mice for many respiratory and other viral infections like RSV, influenza, and HSV. Its business revolves around providing fee-for-service research, developing proprietary reagents, and supplying animals to academic and commercial clients, positioning it as a niche expert in preclinical infectious disease research. The company's work has directly supported the advancement of clinical candidates, most notably prophylactic antibodies for RSV.
Technology Platform
Specialized cotton rat (Sigmodon species) animal model for preclinical research on human infectious diseases, supported by a proprietary toolkit of species-specific reagents and deep genetic/immunological expertise.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
SBI competes within the broader preclinical CRO market and specifically in the niche of specialized animal models. Direct competitors include other CROs offering cotton rat services (e.g., certain university-affiliated facilities) and providers of alternative models like ferrets, hamsters, or humanized mice for infectious disease. Its competitive edge is its deep, focused expertise, proprietary reagents, and established reputation as the leading authority on the cotton rat model.